These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 37654003)
1. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia. Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003 [TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
3. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma. Nylund P; Nikkarinen A; Ek S; Glimelius I Front Immunol; 2024; 15():1373269. PubMed ID: 38566987 [TBL] [Abstract][Full Text] [Related]
4. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages. Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C Front Immunol; 2022; 13():929339. PubMed ID: 36389667 [TBL] [Abstract][Full Text] [Related]
5. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043 [TBL] [Abstract][Full Text] [Related]
6. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy. Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099 [TBL] [Abstract][Full Text] [Related]
7. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619 [TBL] [Abstract][Full Text] [Related]
8. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features. Rasmussen PK Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159 [TBL] [Abstract][Full Text] [Related]
9. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608 [TBL] [Abstract][Full Text] [Related]
11. CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma. Freile JÁ; Ustyanovska Avtenyuk N; Corrales MG; Lourens HJ; Huls G; van Meerten T; Cendrowicz E; Bremer E Biomedicines; 2022 May; 10(5):. PubMed ID: 35625912 [TBL] [Abstract][Full Text] [Related]
12. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686 [TBL] [Abstract][Full Text] [Related]
13. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer. Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058 [TBL] [Abstract][Full Text] [Related]
15. Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression. Cao X; Wang Y; Zhang W; Zhong X; Gunes EG; Dang J; Wang J; Epstein AL; Querfeld C; Sun Z; Rosen ST; Feng M Blood; 2022 Jun; 139(22):3290-3302. PubMed ID: 35134139 [TBL] [Abstract][Full Text] [Related]
16. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Chao MP; Alizadeh AA; Tang C; Myklebust JH; Varghese B; Gill S; Jan M; Cha AC; Chan CK; Tan BT; Park CY; Zhao F; Kohrt HE; Malumbres R; Briones J; Gascoyne RD; Lossos IS; Levy R; Weissman IL; Majeti R Cell; 2010 Sep; 142(5):699-713. PubMed ID: 20813259 [TBL] [Abstract][Full Text] [Related]
17. Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade. Anderson KL; Snyder KM; Ito D; Lins DC; Mills LJ; Weiskopf K; Ring NG; Ring AM; Shimizu Y; Mescher MF; Weissman IL; Modiano JF Melanoma Res; 2020 Apr; 30(2):147-158. PubMed ID: 31205227 [TBL] [Abstract][Full Text] [Related]
18. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma. Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603 [TBL] [Abstract][Full Text] [Related]
19. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Lim SH; Vaughan AT; Ashton-Key M; Williams EL; Dixon SV; Chan HT; Beers SA; French RR; Cox KL; Davies AJ; Potter KN; Mockridge CI; Oscier DG; Johnson PW; Cragg MS; Glennie MJ Blood; 2011 Sep; 118(9):2530-40. PubMed ID: 21768293 [TBL] [Abstract][Full Text] [Related]
20. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy. Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]